7,275
Views
15
CrossRef citations to date
0
Altmetric
Research Article

Profile of medical care costs in patients with amyotrophic lateral sclerosis in the Medicare programme and under commercial insurance

, , , , &
Pages 134-142 | Received 08 Mar 2017, Accepted 23 Jul 2017, Published online: 11 Sep 2017

References

  • Vucic S, Rothstein JD, Kiernan MC. Advances in treating amyotrophic lateral sclerosis: insights from pathophysiological studies. Trends Neurosci. 2014;37:433–42.
  • Bäumer D, Talbot K, Turner MR. Advances in motor neurone disease. J R Soc Med. 2014;107:14–21.
  • Miller RG, Jackson CE, Kasarskis EJ, England JD, Forshew D, Johnston W, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2009;73:1218–26.
  • Larkindale J, Yang W, Hogan PF, Simon CJ, Zhang Y, Jain A, et al. Cost of illness for neuromuscular diseases in the United States. Muscle Nerve. 2014;49:431–8.
  • López-Bastida J, Perestelo-Pérez L, Montón-Alvarez F, Serrano-Aguilar P, Alfonso-Sanchez JL. Social economic costs and health-related quality of life in patients with amyotrophic lateral sclerosis in Spain. Amyotroph Lateral Scler. 2009;10:237–43.
  • Munsat TM, Rivière M, Swash M, Leclerc C. Economic burden of amyotrophic lateral sclerosis in the United Kingdom. J Med Econ. 1998;1:235–45.
  • Oh J, An JW, Oh SI, Oh KW, Kim JA, Lee JS, et al. Socioeconomic costs of amyotrophic lateral sclerosis according to staging system. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16:202–8.
  • van der Steen I, van den Berg JP, Buskens E, Lindeman E, van den Berg LH. The costs of amyotrophic lateral sclerosis, according to type of care. Amyotroph Lateral Scler. 2009;10:27–34.
  • Boylan K, Levine T, Lomen-Hoerth C, Lyon M, Maginnis K, Callas P, et al. Prospective study of cost of care at multidisciplinary ALS centers adhering to American Academy of Neurology (AAN) ALS practice parameters. Amyotroph Lateral Scler Frontotemporal Degener. 2015;17:119–27.
  • Schepelmann K, Winter Y, Spottke AE, Claus D, Grothe C, Schröder R, et al. Socioeconomic burden of amyotrophic lateral sclerosis, myasthenia gravis and facioscapulohumeral muscular dystrophy. J Neurol. 2010;257:15–23.
  • Connolly S, Heslin C, Mays I, Corr B, Normand C, Hardiman O. Health and social care costs of managing amyotrophic lateral sclerosis (ALS): an Irish perspective. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16:58–62.
  • Gladman M, Dharamshi C, Zinman L. Economic burden of amyotrophic lateral sclerosis: a Canadian study of out-of-pocket expenses. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15:426–32.
  • Athanasakis K, Kyriopoulos II, Sideris M, Rentzos M, Evdokimidis J, Kyriopoulos J. Investigating the economic burden of ALS in Greece: a cost-of-illness approach. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16:63–4.
  • Jennum P, Ibsen R, Pedersen SW, Kjellberg J. Mortality, health, social and economic consequences of amyotrophic lateral sclerosis: a controlled national study. J Neurol. 2013;260:785–93.
  • Hatanaka T, Eguchi N, Deguchi M, Yazawa M, Ishii M. Study of global health strategy based on international trends – promoting universal health coverage globally and ensuring the sustainability of Japan’s universal coverage of health insurance system: problems and proposals. Japan Med Assoc J. 2015;58:78–101.
  • Kroneman M, Boerma W, van den Berg M, Groenewegen P, de Jong J, van Ginneken E. Netherlands: health system review. Health Syst Transit. 2016;18:1–240.
  • Schlitt M. Health care systems in Japan and Germany provide facts, not theories. J Med Assoc Ga. 1993;82:651–5.
  • Weil TP. Health management education in Europe and in the United States: a comparative review and analysis. Health Serv Manage Res. 2013;26:76–85.
  • Weil TP. What can the Canadians and Americans learn from each other's health care systems? Int J Health Plann Manage. 2016;31:349–70.
  • Williams JR, Fitzhenry D, Grant L, Martyn D, Kerr DA. Diagnosis pathway for patients with amyotrophic lateral sclerosis: retrospective analysis of the US Medicare longitudinal claims database. BMC Neurol. 2013;13:160.
  • Kowal SL, Dall TM, Chakrabarti R, Storm MV, Jain A. The current and projected economic burden of Parkinson's disease in the United States. Mov Disord. 2013;28:311–18.
  • Centers for Medicare & Medicaid Services. Alpha-Numeric HCPSC. 2012. [cited 3 March 2017]; Available from: https://www.cms.gov/Medicare/Coding/HCPCSReleaseCodeSets/Alpha-Numeric-HCPCS.html.
  • Roche JC, Rojas-Garcia R, Scott KM, Scotton W, Ellis CE, Burman R, et al. A proposed staging system for amyotrophic lateral sclerosis. Brain. 2012;135:847–52.
  • Keehan SP, Poisal JA, Cuckler GA, Sisko AM, Smith SD, Madison AJ, et al. National health expenditure projections, 2015-25: economy, prices, and aging expected to shape spending and enrollment. Health Aff (Millwood). 2016;35:1522–31.
  • Talbott EO, Malek AM, Lacomis D. The epidemiology of amyotrophic lateral sclerosis. Handb Clin Neurol. 2016;138:225–38.
  • Karceski S, Duran J. Using stem cells to treat ALS. Neurology. 2016;87:e42–4.
  • Obermann M, Lyon M. Financial cost of amyotrophic lateral sclerosis: a case study. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16:54–7.